Spring Creek Capital’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Spring Creek Capital’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,000	Closed	-$40K	–	525
2022 Q1	$40K	Hold	200,000	–	–	﹤0.01%	599
2021 Q4	$108K	Hold	200,000	–	–	﹤0.01%	461
2021 Q3	$120K	Hold	200,000	–	–	0.01%	382
2021 Q2	$152K	Buy	+200,000	New	+$121K	0.01%	372

Other funds holding IBER.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Spring Creek Capital's IBER.WS Position: Q2 2022 in Review

Spring Creek Capital sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q2 2022, closing a stake of 200,000 shares — an estimated $40K sold.

Spring Creek Capital first reported a position in IBER.WS in Q2 2021 and held it in 4 quarters. The position peaked at $152K in Q2 2021. 37 funds tracked by Wall St. Rank hold IBER.WS as of Q2 2022.

Spring Creek Capital reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 200,000 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q2 2022, an estimated $40K.
Spring Creek Capital first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 4 quarters.
Spring Creek Capital's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $152K in Q2 2021.
37 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.